UHNM joins Myeloma UK Clinical Trial Network

Myeloma UK news, Patient advocacy news, Research news // 26th July 2017

University Hospitals of North Midlands NHS Trust (UHNM) is the latest organisation to join the Myeloma UK Clinical Trial Network (CTN).

Coordinated by the Clinical Trials Research Unit at the University of Leeds, the CTN brings together leading experts, hospitals and research centres across the UK to run a portfolio of early phase clinical trials into promising new myeloma treatments.

As a member of the CTN, the Research and Development Department at UHNM will help myeloma patients across Staffordshire access the latest, innovative myeloma treatments.

It is currently recruiting for the Myeloma UK trials MUK seven and MUK eight, as well as national myeloma trial Myeloma XII, with further commercial trials in the pipeline.

Myeloma UK Director of Research, Dr Simon Ridley, said, “We are delighted that UHNM has joined the growing number of hospitals across the UK taking part in our Clinical Trial Network. As an incurable and relapsing cancer, it is imperative that myeloma patients get access to as many treatment options as possible.”

He added, “Our Clinical Trial Network is focused on ensuring that patients now and in the future are getting access to the exciting new treatment combinations we see coming down the line, and by taking part in the Clinical Service Excellence Programme, UHMN are also clearly demonstrating their commitment to providing a high-quality service for myeloma patients in their care.”

 

Our Clinical Trial Network is focused on ensuring that patients now and in the future are getting access to the exciting new treatment combinations we see coming down the line, and by taking part in the Clinical Service Excellence Programme, UHMN are also clearly demonstrating their commitment to providing a high-quality service for myeloma patients in their care.

Myeloma UK Director of Research, Dr Simon Ridley

Dr Kamaraj Karunanithi, Consultant Haematologist and Clinical Lead for myeloma and plasma cell disorders at UHNM, has been chosen as Principal Investigator to run the first Myeloma UK trial at UHNM.

He said, “I am very happy with the progress the Myeloma Team here at UHNM is making. Membership in the CTN will provide opportunity for our patients to access newer drugs.

“I am also delighted that we are now another step closer to joining the Myeloma UK Clinical Service Excellence Programme, as this will support UHNM in delivering the best possible treatment and care for myeloma patients.”

For more information on the Clinical Trial Network, visit myeloma.org.uk/clinical-trial-network. You can find out more information about the treatments involved and the current status of our trials in our clinical trials portfolio.